Development of an LC-MRM-MS-based candidate reference measurement procedure for standardization of serum apolipoprotein (a) tests

Ruhaak, L.R.; Romijn, F.P.H.T.M.; Brkovic, I.B.; Kuklenyik, Z.; Dittrich, J.; Ceglarek, U.; ... ; Int Federation Clinical Chem Lab (2023)

Article / Letter to editor

Background: Medical results generated by European CE Marking for In Vitro Diagnostic or in-house tests should be traceable to higher order reference measurement systems (RMS), such as International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)-endorsed reference measurement procedures (RMPs) and reference materials. Currently, serum apolipoprotein (a) [apo(a)] is recognized as a novel risk factor for cardiovascular risk assessment and patient management. The former RMS for serum apo(a) is no longer available; consequently, an International System of Units (SI)-traceable, ideally multiplexed, and sustainable RMS for apo(a) is needed. Methods: A mass spectrometry (MS)-based candidate RMP (cRMP) for apo(a) was developed using quantitative bottom-up proteomics targeting 3 proteotypic peptides. The method was provisionally validated according to ISO 15193 using a single human serum based calibrator traceable to the former WHO-IFCC RMS. Results: The quantitation of serum apo(a) was by design independent of its size polymorphism, was linear from 3.8 to 456 nmol/L, and had a lower limit of quantitation for apo(a) of 3.8 nmol/L using peptide LFLEPTQADIALLK. Interpeptide agreement showed Pearson Rs of 0.987 and 0.984 for peptides GISSTVTGR and TPENYPNAGLTR, and method comparison indicated good correspondence (slopes 0.977, 1.033, and 1.085 for LFLEPTQADIALLK, GISSTVTGR, and TPENYPNAGLTR). Average within-laboratory imprecision of the cRMP was 8.9%, 11.9%, and 12.8% for the 3 peptides. Conclusions: A robust, antibody-independent, MS-based cRMP was developed as higher order RMP and an essential part of the apo(a) traceability chain and future RMS. The cRMP fulfils predefined analytical performance specifications, making it a promising RMP candidate in an SI-traceable MS-based RMS for apo(a).

• All authors: Ruhaak, L.R.; Romijn, F.P.H.T.M.; Brkovic, I.B.; Kuklenyik, Z.; Dittrich, J.; Ceglarek, U.; Hoofnagle, A.N.; Althaus, H.; Angles-Cano, E.; Coassin, S.; Delatour, V.; Deprez, L.; Dikaios, I.; Kostner, G.M.; Kronenberg, F.; Lyle, A.; Prinzing, U.; Vesper, H.W.; Cobbaert, C.M.; Int Federation Clinical Chem Lab
• Date: 2023-01-16
• Journal: Clinical Chemistry
• Volume: 69
• Issue: 3
• DOI: doi:10.1093/clinchem/hvac204